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Abstract
Background: Evaluations of diagnostic tests are challenging because of the indirect nature of their impact on patient
outcomes. Model-based health economic evaluations of tests allow different types of evidence from various sources to
be incorporated and enable cost-effectiveness estimates to be made beyond the duration of available study data. To
parameterize a health-economic model fully, all the ways a test impacts on patient health must be quantified,
including but not limited to diagnostic test accuracy.
Methods: We assessed all UK NIHR HTA reports published May 2009-July 2015. Reports were included if they
evaluated a diagnostic test, included a model-based health economic evaluation and included a systematic
review and meta-analysis of test accuracy. From each eligible report we extracted information on the following topics:
1) what evidence aside from test accuracy was searched for and synthesised, 2) which methods were used to
synthesise test accuracy evidence and how did the results inform the economic model, 3) how/whether
threshold effects were explored, 4) how the potential dependency between multiple tests in a pathway was
accounted for, and 5) for evaluations of tests targeted at the primary care setting, how evidence from differing
healthcare settings was incorporated.
Results: The bivariate or HSROC model was implemented in 20/22 reports that met all inclusion criteria. Test accuracy
data for health economic modelling was obtained from meta-analyses completely in four reports, partially in
fourteen reports and not at all in four reports. Only 2/7 reports that used a quantitative test gave clear threshold
recommendations. All 22 reports explored the effect of uncertainty in accuracy parameters but most of those that
used multiple tests did not allow for dependence between test results. 7/22 tests were potentially suitable for
primary care but the majority found limited evidence on test accuracy in primary care settings.
Conclusions: The uptake of appropriate meta-analysis methods for synthesising evidence on diagnostic test
accuracy in UK NIHR HTAs has improved in recent years. Future research should focus on other evidence
requirements for cost-effectiveness assessment, threshold effects for quantitative tests and the impact of
multiple diagnostic tests.
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Background
Just like any other intervention or medical device, diag-
nostic tests require rigorous evaluation before being im-
plemented in clinical practice. Evaluations of diagnostic
tests are notoriously complex, however, in part because of
the indirect nature of their impact on patient outcomes.
Economic evaluations are now intrinsic to adoption
decisions; many guideline bodies will not recommend a
test for use in clinical practice without evidence of its
cost-effectiveness [1–4]. Model-based health economic
evaluations of tests have become increasingly popular as
they allow many different types of evidence to be consid-
ered and incorporated, as well as enabling estimates of
cost-effectiveness to be made beyond the duration of
any single study. To facilitate this analysis, evidence
should preferably be synthesised from all aspects of the
care pathway in which the test is used.
Economic decision models typically require informa-
tion about test accuracy to estimate the proportion of
patients on each care pathway following a particular test
outcome, and to weight the associated costs and health
outcomes [1]. Test accuracy studies, however, are prone
to many types of bias and formulating study designs that
produce high quality evidence can be challenging [5].
Additional complexities arise when attempting to syn-
thesise evidence from different test accuracy studies.
One statistical complication is that accuracy is typically
summarised using two linked, dependent outcomes: sen-
sitivity (the accuracy of the test in patients with the tar-
get condition) and specificity (the accuracy of the test in
patients without the target condition) [6]. Statistical
models which account for these correlated outcomes,
such as the bivariate model and the Hierarchical Summary
Receiver Operating Characteristic (HSROC) model, are
now advocated as best practice [5, 7–9].
In 2009, Novielli et al. conducted a systematic review
of UK NIHR Health Technology Assessment (HTA) re-
ports that had carried out economic evaluations of diag-
nostic tests [10]. They evaluated the methods used to
synthesise evidence on test accuracy, specifically, and
looked at how these results were subsequently incorpo-
rated into economic decision models. Very few of the re-
ports implemented meta-analysis methods that accounted
for the correlation between sensitivity and specificity.
Since this review, significant work has been carried out to
make best practice methods for the meta-analysis of diag-
nostic accuracy more accessible [7, 11, 12].
The authors also highlighted two potential methodo-
logical problem areas in their discussion: 1) how thresh-
olds were dealt with in the evaluation of quantitative
tests, and 2) how reviews account for the potential de-
pendency in performance for combinations of tests [5].
The first issue relates to tests that produce numerical re-
sults which are subsequently categorised into ‘positives’
or ‘negatives’ by selecting a specific threshold. The
threshold at which accuracy is reported can differ be-
tween primary studies, causing problems when pooling
results in a meta-analysis. A lot of work has been carried
out in recent years to develop methods to overcome this
issue [13–16], but the extent to which they are being
used is unclear. The second issue arises when more than
one test is being evaluated within a clinical pathway and
the performance of one impacts on the other (see [17]
for more information).
An additional challenge we encounter frequently is the
paucity of diagnostic accuracy evidence from the pri-
mary care setting. Conducting diagnostic accuracy re-
search in primary care is challenging due to low disease
prevalence, inflating both research time and costs [18].
As a consequence, much of the evidence for tests used
in general practice has been acquired in secondary care
settings [19]. Although it is well known that the predict-
ive value of a test is dependent on the prevalence of the
condition in question, it has only recently been acknowl-
edged that test characteristics such as sensitivity and
specificity also vary across clinical settings due to differ-
ing spectrums of disease severity [20]. These findings
bring to question the transferability of evidence gener-
ated in secondary care to primary care.
The main objective here is to review current methods
used to synthesise evidence to inform economic decision
models in Health Technology Assessments of diagnostic
tests. We update Novielli et al.’s original review, but also
expand to formally assess the methodological issues
outlined.
Methods
Inclusion criteria
We screened all 480 UK NIHR HTA reports published
between May 2009 (the end date of the Novielli et al. re-
view [10]) and July 2015 (Volume 19, Issue 52 of the
NIHR HTA Journals Library).
In an initial screen, we determined whether each re-
port evaluated an intervention or treatment; evaluated a
test or multiple tests; focused on methodological devel-
opment; or fell into none of these categories (for ex-
ample, purely observational studies such as [21]). Of
those that evaluated at least one test, we classified the
primary role of the test as either screening, diagnosis,
prognosis, monitoring or treatment selection based on
the abstract of the HTA report. The last of these cat-
egories, which was not considered by Novielli et al. [10],
was included to recognise that the purposes of some
HTA reports is to use test results to guide a suitable
choice of treatment in a particular patient group; see
[22] for an example of a report that falls into this cat-
egory. The five categories are not mutually exclusive, as
some reports have multiple objectives, so for the
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purposes of our study, precedence was given to the
‘diagnosis’ classification if a report additionally fell into
one of the other categories.
We then assessed the full texts of those that evaluated
a diagnostic test to identify those that included both a
model-based health economic evaluation and a system-
atic review. Those that carried out a systematic review
were categorised further according to whether they con-
ducted a formal meta-analysis of diagnostic test accuracy
results (defined as the statistical pooling of quantitative
study outcomes) as part of their systematic review,
which was the final criterion for inclusion.
We additionally scrutinised two groups of reports that
fell outside our original inclusion criteria. Firstly, we
looked at reports of diagnostic tests that conducted a
systematic review but did not carry out a meta-analysis,
as we were interested in the factors that led the authors
of these reports to use results summaries other than
meta-analysis. Secondly, we considered prognostic stud-
ies that conducted both a health economic evaluation
and a meta-analysis, in the expectation that the method-
ology used for diagnostic studies is often equally applic-
able in a prognostic setting [23].
Data extraction
A data extraction spreadsheet was developed (a list of
all of the information extracted is available in the
Additional file 1).
The search criteria from each systematic review was
extracted to determine whether the authors specifically
looked for evidence on test-related outcomes or patient
outcomes, rather than only diagnostic accuracy results,
when deciding which studies to include. Test-related
outcomes includes items such as test failure rate, time to
test result, proportion of inconclusive test results, and
interpretability of the test results. Patient outcomes re-
fers to items that capture the downstream consequences
of the test for the patient, including clinical decisions in
terms of further tests, treatment and management for
patients, and associated health service utilization and
costs, as well as patient health outcomes such as survival
and/or health related quality of life. We also recorded
which reviews presented information about test-related
outcomes or patient outcomes in their report, whether
or not these outcomes had been included in the search
criteria. Thus this evidence was classified as ‘systematic-
ally searched for’, ‘some evidence reported but not
systematically searched for’, or ‘neither systematically
searched for nor reported’.
For studies that reported a meta-analysis, we extracted
the following key information: 1) the outcomes synthe-
sised, 2) whether a formal quality assessment of the in-
cluded studies was carried out, 3) the statistical methods
used to synthesise test outcomes, and 4) whether these
pooled outcomes were included in the subsequent health
economic analyses. If a report contained more than one
diagnostic test, it was regarded as having included the
relevant information if this was reported in any of the
tests considered.
For the group of studies that carried out a systematic
review but did not present a meta-analysis, we reviewed
the methods section of the report to ascertain if a meta-
analysis had been planned and, if so, the reasons it was
not carried out or not reported.
Apart from the above, we were also particularly inter-
ested in three other factors and extracted data on: 1)
how threshold effects were explored/analysed in evalua-
tions of tests that produce quantitative results, 2) how
evidence from different healthcare settings from the one
of interest was handled, and 3) how reviews incorpo-
rated information from multiple tests as part of a treat-
ment pathway.
The whole screening and extraction process was car-
ried out independently by two researchers (BS and TRF).
If required, disagreements were resolved by an additional
researcher (LA or YY).
Results
Search results
A flowchart of the search results and reasons for inclu-
sions can be found in Fig. 1. Of the 480 UK NIHR HTA
reports considered, 110 (23%) evaluated a test, and
around half of these (53) were for the purpose of diagno-
sis. The 18 reports of diagnostic tests that were excluded
because they did not include a systematic review tended
to include primary research which informed the eco-
nomic model parameters. A total of 35 reports [24–58]
included a health economic evaluation of at least one
diagnostic test and a systematic review, and 22 of these
[37–58] reported the results of a meta-analysis as part of
their systematic review. Additionally, there was a single
report of a prognostic test, a study of foetal fibronectin
testing to predict pre-term birth [59], that included both
an economic evaluation, a systematic review, and a
meta-analysis of the accuracy of the prognostic test.
Evidence reviewed in addition to diagnostic accuracy
In addition to diagnostic accuracy outcomes, evidence
on test-related outcomes (8/22 reports) [37, 44, 45, 47,
50, 51, 56, 57] and patient outcomes (11/22 reports)
[37, 44, 45, 47, 49–51, 54, 56–58] was also explicitly
searched for in the systematic reviews. Additionally,
four reports presented information about test-related
outcomes [40, 52, 53, 55] and four presented informa-
tion about patient outcomes [39, 52, 53, 55] without
these being systematically searched for, according to the
search criteria. When available, evidence on test-related
outcomes was summarised descriptively. Patient outcome
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evidence was often not available, or was available
from only one or two studies, which were not always
randomised trials. Of the fifteen reviews that reported
patient outcome data, only three identified sufficient
evidence for meta-analysis [44, 49, 53]; the remainder
identified no or little evidence, thereby negating the
possibility of meta-analysis.
Meta-analysis methods and reporting
Of the 13 reports that carried out a diagnostic accuracy
systematic review but did not present a meta-analysis, a
meta-analysis had been planned but not carried out in all
but two: one of these was an initial scoping exercise [24],
and the other presented pooled summary estimates of
treatment effectiveness but not the diagnostic test under
consideration [36]. Of the other 11, a high level of clinical
and/or statistical heterogeneity was the primary explan-
ation most commonly given for not reporting a meta-
analysis, although some reported finding insufficient or
inadequate data in the primary studies [29, 30, 35] and one
cited “the overwhelming positive nature of all of the results
regarding the analytical validity of each of the tests” [28].
In all 22 reports meeting the inclusion criteria, the
QUADAS or QUADAS2 checklist (depending on the
timing of the report) was used to evaluate the quality of
the diagnostic accuracy studies included in the reviews
[60]. Table 1 shows the statistical methods used to
synthesise the evidence on test accuracy and the pooled
summary statistics presented following meta-analysis.
The bivariate model or the equivalent HSROC model
(including variants that use a Bayesian framework) were
implemented for the primary analysis in all but two re-
ports [42, 57]. Many of these reports had to resort to
statistical models that do not account for the correlation
between sensitivity and specificity (e.g. fitting two separ-
ate random or fixed effects logistic regressions for sensi-
tivity and specificity, setting the correlation parameter to
zero in the bivariate model) for some secondary meta-
analyses due to the small number of studies or conver-
gence issues.
Forest plots depicting the between-study heterogeneity
of sensitivity and specificity estimates were presented in
16 of the 22 reports, and estimates from contributing
studies were displayed in ROC space (with or without an
overlaid fitted summary ROC curve) in 18 reports.
Other less common graphical methods used include
Fagan’s nomogram for likelihood ratios [55], a plot to
show the change in sensitivity and specificity according
to changes in the quantitative threshold [44], and a
graph of pre-test against post-test probabilities [48]. For-
mal quantification of heterogeneity using I2 or the chi-
squared test was presented in 11 reports.
A wide variety of software was used to carry out the
meta-analyses, Stata (in particular, the glamm and
Fig. 1 Flowchart of screening strategy
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metandi functions [11]) being the most popular (used in
11/22 studies). Other software packages used include
MetaDiSc, R (the now defunct diagmeta package), Re-
view Manager, SAS (the METADAS and NLMIXED
macros) and WinBUGS.
Summary of other outcomes
Investigation of Threshold Effects
Seven of the 22 reports evaluated at least one diag-
nostic test that produced fully quantitative results [38,
40, 43, 44, 52, 55, 58]. Additionally, one report used
an individual participant data (IPD) meta-analysis [48]
which, by its nature, allows a range of quantitative
thresholds to be considered and which is discussed
separately below. Two other reports used a test that
was partially quantitative, in the sense that the diag-
nostic decision was based on both quantitative and
qualitative information, but the final decision could
not be expressed based simply on a numerical score
or measurement [37, 42].
Accuracy was reported at differing thresholds across
primary studies within each of the seven diagnostic re-
ports that evaluated quantitative tests. Five of these
reports found at least one study in their systematic re-
view that reported diagnostic accuracy at more than one
threshold. All but one of these reports [43] showed a
summary ROC curve to depict how accuracy varied at
different thresholds. Six attempted to quantify threshold
effects – the tendency of diagnostic performance to vary
according to the threshold used to define test positivity
– but only two [44, 55] were able to provide unambigu-
ous recommendations about the threshold practitioners
should use. Even among these, one [55] was hindered by
limited primary evidence about the performance of fae-
cal calprotectin for the diagnosis of inflammatory bowel
disease at thresholds other than 50 μg/g, and in the
other [44] the authors were able to investigate threshold
effects for only one (the Edinburgh Postnatal Depression
Scale) of the 14 measures considered for the identifica-
tion of postnatal depression in primary care.
The single relevant report that considered a prognostic
score found that all primary studies in the systematic re-
view that reported the threshold used the same standard
foetal fibronectin value of above 50 ng/ml to define a
positive test result.
Individual patient data (IPD) meta-analysis
In one report [48], which looked at patient signs and
symptoms as factors in the diagnosis of heart failure, the
authors wanted to explore the diagnostic potential of
several variables simultaneously, with the restriction that
variables were required to be obtainable in a general
practice setting. In many scenarios, the performance of
diagnostic tests are reported on a ‘per variable’ basis,
without any attempt to perform multivariable adjust-
ment or create a combined diagnostic score. In contrast,
several previous heart failure diagnostic and prognostic
models had previously been developed [61], some of
which found widespread use, although the large number
of variables required to be collected means that not all
are suitable for primary care.
To overcome this issue, the authors obtained full
patient-level data from nine of the primary cohorts that
they had identified in their systematic review. They then
used these in an IPD meta-analysis to create a series of
seven new candidate diagnostic scores using logistic re-
gression modelling, although the presence of heterogen-
eity meant that data from only one of the primary
studies were used to develop the model; data from the
other studies were used for validation. The IPD allowed
the authors not only to develop the diagnostic models,
but also to test the resulting scores were adequately cali-
brated and to investigate the effect of changing the
threshold for test positivity on diagnostic performance,
with a view to creating a usable set of decision rules suit-
able for general practice. Results are presented in terms
of pre-test and post-test probabilities of heart failure.
Table 1 Summary of methods and reporting used in the
meta-analysis of diagnostic accuracy data
Assessment Item No. of meta-analyses
(/22)
Primary model used to pool accuracy data
Bivariate or HSROC model 20
Independent models for sensitivity and
specificity
2
Pooled accuracy statistics reported
Sensitivity and specificity 22
Positive and negative likelihood ratio 11
Positive and negative predictive value 1
Diagnostic odds ratio 9
Area under the ROC curve 1
Exploration of Heterogeneity
Subgroup analysis 14
Multivariable adjustment 3
Heterogeneity quantified (e.g. using
I2 measure)
11
Presentation of Results
Forest plot 16
Plot in ROC space/summary ROC curve 18
Investigation of Threshold Effects
Evaluated a quantitative index test 7 (excluding 1 IPD
analysis)
Existence of threshold effect clearly identified 4
Clear threshold recommendations presented 2
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Health care setting
The report of Mant et al. was one of only three [44, 45, 48]
in our final sample that aimed unambiguously to assess a
diagnostic test for use in primary care or as a point-of-care
test, and was also unusual in that its IPD analysis specified
a primary care setting as an inclusion criteria. Four other
reports [40, 41, 53, 55] considered tests that were poten-
tially usable or primary care, or which might be used across
different health settings.
These reports did not restrict their search to studies
conducted in primary care, and did not distinguish be-
tween setting when conducting the meta-analysis. In-
deed, for most of these reports, few or no studies based
in a primary care setting were found and so the authors
were unable to assess whether test accuracy was the
same in primary and secondary care. For example, the
faecal calprotectin report of Waugh et al. [55] specific-
ally recommends studies in primary care populations as
a future research need. Similarly, Drobniewski et al. [41]
discuss the need for further research in targeted patient
populations for the use of molecular tests for antibiotic
resistance in tuberculosis as point-of-care tests; the ma-
jority of primary studies included in that report were
conducted in a laboratory environment.
Health economic modelling
In extracting information about the types of health eco-
nomic decision analytic models implemented, we found
that the methodology was often described using differing
terminology and reported in varying level of detail. The
two most common classes of models adopted were deci-
sion trees and Markov models, although the precise
form of the model varied, and other model formulations
guided by the healthcare context (e.g. [43, 47, 55]) were
also used.
The extent to which the results of the test accuracy
meta-analyses informed the model parameters in the cost-
effectiveness analyses was evaluated. Four of the test
accuracy meta-analyses, including the one IPD meta-
analysis [48], provided all of the accuracy data required for
the cost-effectiveness modelling [38, 44, 48, 58]. In four-
teen reports, some of the accuracy parameters had to be
informed by single studies, expert opinion, or assumptions
[39–41, 43, 45–47, 50–53, 55–57], including one in which
the results of the meta-analysis had to be adjusted to ac-
count for the fact that the reference standard used was
not 100% accurate [46]. In four reports, the results of the
diagnostic accuracy meta-analysis were not used to in-
form the cost-effectiveness analyses. Instead, accuracy
model parameters were either extracted from single
studies [37, 54] or elicited from clinicians [49], or based
on a combination of these [42].
In all 22 of the reports, some attempt was made to ex-
plore the effect of uncertainty in the accuracy estimates,
typically via one-way (univariate), extreme case or, more
commonly, probabilistic sensitivity analysis.
Of the seven reports that evaluated the cost-
effectiveness of a fully quantitative test, the majority (6/
7) explored how differing the threshold impacted on the
cost-effectiveness of the test. This was, however, re-
stricted to the few thresholds at which sufficient data
was available for meta-analysis or a sub-group analysis.
In contrast, threshold was included as a full parameter
in the cost-effectiveness model where IPD was available
and ‘optimised’ against willingness to pay [48].
Multiple tests within the diagnostic pathway
The majority of reports (16/22) considered the effect of
a combination of tests within the diagnostic pathway
into their decision model. This includes both scenarios
in which a new test is being added to an existing one,
possibly at a different point in the pathway and those in
which multiple tests are evaluated concurrently. Most of
these reports did not discuss the issue of possible de-
pendence between multiple tests being evaluated on the
same individual, or made an explicit assumption that the
tests were being regarded as independent, calculating re-
quired joint probabilities via Bayes rule (e.g. [53]). Two
reports tested the assumption of independence in a sen-
sitivity analysis [46, 52].
Discussion
This review assesses current methods used to synthesise
evidence to inform economic decision models in Health
Technology Assessments of diagnostic tests.
In six years of UK NIHR HTA reports published since
2009, there has been a notable improvement in the qual-
ity of meta-analytic methods used by authors. During
the period 1997-May 2009, only two of fourteen reports
used the bivariate or the HSROC model for meta-
analysing diagnostic accuracy data across studies [10]. In
the subsequent period, to July 2015, this figure rose to
20 out of 22. Our conclusion is that during the last six
years, these methods are now routinely accepted as
standard practice within UK NIHR HTAs. Priority areas
for methodological improvement within future UK
NIHR HTAs of diagnostic tests are outlined below.
Priority area 1: Evidence requirements for cost-effectiveness
evaluations of tests
Most reports focused their systematic reviews on test ac-
curacy. Many did look for other outcomes at the same
time, but not all. It was difficult to formally assess
whether each systematic review had looked for evidence
on all the necessary outcomes to inform the cost-
effectiveness model as there is poor agreement on what
evidence is required to inform adoption decisions for
tests, and the evidence required is likely to depend
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heavily on the context. One systematic review identified
19 different ‘phased evaluation schemes’ for medical
tests [62].
Nevertheless, the distinct lack of evidence identified
on the impact of a test on patient outcomes was notable.
Randomised controlled trials in this setting are often im-
practical due to long follow-up periods required to cap-
ture downstream patient outcomes, large sample sizes
and the speed at which technology is advancing in this
area (see [63] for further discussion on this topic). Often
the technology has developed or changed by the time
the trial is complete [64]. To overcome this issue, some
studies have used a linked evidence approach (e.g. [65])
and carried out two separate reviews – one looking at
outcomes related to the test and another focusing on the
impact of therapeutic changes on morbidity, mortality
and adverse effects.
There currently lacks a clear framework that describes
the evidence required for cost-effectiveness evaluations
of tests. For the time being, we would recommend that
authors use this checklist [66] to identify outcomes po-
tentially relevant to their research question and tailor
their systematic literature searches accordingly. The
same rigour implemented for the systematic searches for
test accuracy evidence should also be applied for other
outcomes, if the objective is to evaluate the diagnostic
pathway holistically.
Priority area 2: The evaluation of threshold effects in
quantitative tests
Ideally, thresholds should be selected that balance the
repercussions of a false negative and false positive result
in terms of patient outcomes and costs. The accuracy of a
diagnostic test is typically evaluated by calculating paired
summary statistics from a 2 × 2 classification table (e.g.
sensitivity and specificity). Even for quantitative tests, clin-
ical application often involves the selection of a single
threshold to guide treatment decisions, and therefore ac-
curacy needs to be summarised at this threshold. Perhaps
for this reason, primary diagnostic accuracy often report
accuracy measures at just one threshold, which can limit
the opportunity to pool accuracy at all thresholds and
make comparisons between them in a meta-analysis.
Of the seven (non-IPD) reports that evaluated quanti-
tative tests, the authors were able to make clear optimal
threshold recommendations in only two. In the one re-
port that carried out an IPD meta-analysis [48], diagnos-
tic accuracy was pooled across the whole test scale,
allowing it to be incorporated as a parameter that could
be optimised when fitting the cost-effectiveness model.
The authors were thus able to identify and recommend
the threshold which provided optimal clinical- and cost-
effectiveness. The issue of threshold selection is likely to
be of particular importance when assessing whether test
accuracy is transferrable between different settings, such
as from secondary to primary care, as health settings
may differ in their patient populations and in the level of
accuracy that is required for the test to be adopted.
Statistical methods have been proposed to overcome
this issue [13–16], but they are generally only possible to
implement if accuracy is reported at multiple thresholds
within a single study, or at a broad range of thresholds
across different studies. We recommend where possible
that 2 × 2 data is obtained across all thresholds from
each study to allow accuracy to be summarised across
the whole test scale and thus available as a parameter
for subsequent cost-effectiveness analyses. Alternatively,
researchers might consider making entire data files
available for future evidence synthesis via IPD analysis, a
practice which is already encouraged or required by
some journals.
Priority area 3: The evaluation of test combinations
within the diagnostic pathway
Many treatment pathways rely on results from multiple
diagnostic tests, either performed in parallel or in se-
quence. Our results show that the majority of UK NIHR
HTA reports that consider test combinations treat them
as independent. The few that do consider the dependence
caused by performing two or more tests on the same indi-
vidual are often restricted by a lack of evidence about the
extent of the dependence from primary studies.
We suggest two possible strategies for dealing with this
issue in future diagnostic treatment evaluations. The first,
and simplest, is to conduct sensitivity analysis assuming
different quantitative estimates of within-individual correl-
ation between test results [46, 52]. The second is to con-
duct primary studies, including randomised trials, which
consider the entire treatment pathway as the intervention,
rather than only a single component. This approach, al-
though considered by some of the reports in our review
(e.g. [50]), is likely to be costly and may be difficult to
evaluate if the patient pathway is complex. At a minimum,
authors of primary studies should consider reporting in-
formation about between-test correlation or making IPD
data available. Additionally, although some methodo-
logical work has been conducted in this area [67], further
research would be valuable.
Limitations
By including a systematic review as one of the requisites
for inclusion in this review, 7 reports that evaluated at
least one diagnostic test were excluded from this review.
Of these, 6 were based on primary studies conducted as
part of the UK NIHR HTA grant (5 randomised trials
[68–72] and 1 diagnostic accuracy study [73]) and a fur-
ther report based their evaluation on a sub-study of an
existing trial [74].
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Conclusions
The results of this review demonstrate that, within UK
NIHR HTAs, diagnostic accuracy meta-analyses are now
routinely conducted using statistically appropriate methods
that account for the nuances and challenges unique to
diagnostic accuracy research.
Despite this commendable progress, there is still room
for improvement in the methodology applied within
HTAs. There is generally a gap in understanding the evi-
dence requirements to inform cost-effectiveness analyses
of diagnostic tests. More specifically, the evaluation of
quantitative tests remains a challenge due to incomplete
reporting of accuracy across thresholds. Greater efforts
are also required to ensure that potential dependencies
in test performance are accounted for when tests are
used sequentially within a diagnostic pathway.
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